Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9551
Name smoldering myeloma
Definition A multiple myeloma that is a slow growing type of myeloma in which abnormal plasma cells results_in too much of a single type of monoclonal antibody.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma smoldering myeloma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02279394 Phase II Dexamethasone Elotuzumab + Lenalidomide Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma Completed USA 0
NCT02886065 Phase I Durvalumab Durvalumab + PVX-410 Durvalumab + Lenalidomide + PVX-410 A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma Active, not recruiting USA 0
NCT02903381 Phase II Dexamethasone + Lenalidomide + Nivolumab Nivolumab + Lenalidomide + Dexamethasone In SMM Completed USA 0
NCT02960555 Phase II Diphenhydramine + Isatuximab + Methylprednisolone + Ranitidine Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT03301220 Phase III Daratumumab + rHuPH20 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 15
NCT03591614 Phase I DKK1 dendritic cell vaccine Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma Withdrawn USA 0
NCT03631043 Phase I Personalized cancer vaccine Personalized Vaccine in Treating Participants With Smoldering Multiple Myeloma Active, not recruiting USA 0
NCT03839459 Phase II Denosumab Denosumab for Smoldering Multiple Myeloma Active, not recruiting USA 0
NCT04270409 Phase III Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT05055063 Phase I belantamab mafodotin-blmf A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT05469893 Phase II Teclistamab Dexamethasone + Lenalidomide Immuno-PRISM (PRecision Intervention Smoldering Myeloma) Recruiting USA 0
NCT05597345 Phase II Selinexor Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT05767359 Phase II Ciltacabtagene autoleucel + Cyclophosphamide + Fludarabine CAR- PRISM (PRecision Intervention Smoldering Myeloma) Recruiting USA 0
NCT06100237 Phase II Daratumumab + Teclistamab Daratumumab + Talquetamab-tgvs Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE) Recruiting USA 0